Carfilzomib Evidence Guide
Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data.
Our Take
Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data.
- Best for
- Relapsed/refractory multiple myeloma, proteasome inhibitor pharmacology, bortezomib-resistant disease
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 20mg/m² IV on days 1 and 2 of cycle 1, then 27mg/m² (ASPIRE/ENDEAVOR dosing)
Benefits and Evidence
- Multiple Myeloma Response: Level A, includes human evidence - Phase 3 ASPIRE trial demonstrated superior progression-free survival when combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone alone in relapsed myeloma.
- Overall Survival Benefit: Level A, includes human evidence - ENDEAVOR trial showed superior overall survival compared to bortezomib in relapsed or refractory multiple myeloma patients.
- Cardiac Toxicity Risk: Level A, includes human evidence - Cardiovascular adverse events including heart failure and cardiac arrest reported in clinical trials. Requires cardiac monitoring.
Side Effects and Warnings
- Fatigue
- Anemia and thrombocytopenia
- Dyspnea
- Hypertension
- Cardiac events (heart failure, arrhythmias)
- Peripheral neuropathy (less than bortezomib)
- Cardiac toxicity - assess cardiac function before and during treatment
- Pulmonary toxicity including ARDS reported
Research Dosage References
- <strong>Intravenous infusion</strong> - 20-56 mg/m2 - Days 1, 2, 8, 9, 15, 16 of 28-day cycle - Cycle 1 starts at 20 mg/m2 on days 1-2, then escalates to 27 or 56 mg/m2 based on regimen. Infuse over 10-30 minutes.
- <strong>Intravenous infusion</strong> - 70 mg/m2 (once-weekly) - Days 1, 8, 15 of 28-day cycle - Once-weekly dosing approved for convenience. Requires prehydration.
Mechanism of Action
Carfilzomib exerts anti-tumor effects through irreversible proteasome inhibition: 1. Irreversible 20S proteasome binding: Covalently binds to the chymotrypsin-like subunit (beta-5) of the 20S proteasome, providing sustained inhibition. 2. Protein homeostasis disruption: Prevents degradation of ubiquitinated proteins, leading to accumulation of misfolded proteins and endoplasmic reticulum stress. 3. NF-kB pathway inhibition: Blocks degradation of IkB, preventing activation of the pro-survival NF-kB signaling pathway. 4. Apoptosis induction: Triggers caspase-dependent apoptosis in myeloma cells through activation of intrinsic and extrinsic apoptotic pathways.
Legal Status
FDA-approved for relapsed or refractory multiple myeloma. Available by prescription only. Administered in healthcare settings. Marketed as Kyprolis by Amgen.
Primary Sources
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (ASPIRE). N Engl J Med, 2015.
- Carfilzomib vs bortezomib in relapsed or refractory myeloma (ENDEAVOR). Lancet Oncol, 2016.
- Cardiovascular adverse events in carfilzomib-treated patients. Blood, 2019.